Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25265
Title: Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Austin Authors: de Boer, Richard;Hui, Rina;Lim, Elgene;Yeo, Belinda ;Zdenkowski, Nicholas
Affiliation: Epworth-Freemasons Private Hospital, Melbourne, Victoria, Australia
Westmead Hospital, Westmead, Sydney, New South Wales, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
University of Newcastle, Newcastle, New South Wales, Australia
Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
Breast Cancer Trials, Newcastle, New South Wales, Australia
Austin Health
Olivia Newton-John Cancer Research Institute
St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Sydney, New South Wales, Australia
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
University of Sydney, Camperdown, Sydney, New South Wales, Australia
Issue Date: Nov-2020
metadata.dc.date: 2020-11
Publication information: Asia-Pacific Journal of Clinical Oncology 2020; 16 Suppl 5: 3-14
Abstract: Treatment strategies for hormone receptor-positive (HR+ ), human epidermal growth factor receptor 2-negative (HER2- ) metastatic breast cancer in young women (<40 years at diagnosis) have traditionally been extrapolated from data obtained from trials conducted either exclusively or predominantly in the postmenopausal setting. These young patients are usually treated with ovarian function suppression (OFS) + endocrine therapy (ET) ± targeted therapy, except if there is a concern about endocrine resistance or a need to gain rapid disease control due to the onset of visceral crisis. This review examines evidence that supports the use of a cyclin-dependent kinase 4/6 inhibitor, in combination with OFS and ET, when treating premenopausal or perimenopausal women with HR+ /HER2- metastatic breast cancer. This includes data from the MONALEESA-7 study (treating only premenopausal/perimenopausal women in the first-line setting), and the results of subgroup analyses from the PALOMA-3 and MONARCH-2 trials. We also consider a number of age-specific challenges that younger breast cancer patients can face, highlighting the importance of a multidisciplinary approach to ongoing care.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25265
DOI: 10.1111/ajco.13461
PubMed URL: 33137857
Type: Journal Article
Subjects: CDK4/6 inhibitor
HER2-negative
endocrine therapy
hormone receptor-positive
metastatic breast cancer
psychosocial
supportive care
younger women
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on May 11, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.